Announcement • Jul 09
Clearone, Inc. and Cortigent, Inc. Announces Executive and Board Changes On July 1, 2026, ClearOne, Inc. entered into an Agreement and Plan of Merger by and among ClearOne, CLRO Merger Sub, Inc., a wholly-owned subsidiary of ClearOne ("Merger Sub"), Cortigent, Inc. ClearOne, Inc. announced at the Effective Time, the post-closing board of directors will consist of five members: Adam Mendelsohn (Chairman), Jonathan Adams, John Bowers, Linda Szyper, and Eric Robinson. Eric Robinson will serve as Chair of the Audit Committee. The officers of the combined company will be: Jonathan Adams (President), Ed Sedo (Principal Accounting Officer), and Rachel Evans (Corporate Secretary). Post-Closing Officers. At the Effective Time, the officers of the combined company will be: Jonathan Adams (President & CEO), Ed Sedo (CFO and Principal Accounting Officer), and Rachel Evans (Corporate Secretary). Live News • Jul 04
ClearOne to Combine With Cortigent in Merger With $10 Million to $15 Million Financing Vivani Medical has entered a definitive merger agreement to combine its wholly owned neurostimulation subsidiary Cortigent, Inc. with Nasdaq-listed ClearOne, after which Cortigent will become a wholly owned subsidiary of ClearOne and the company will be renamed Cortigent Holdings, Inc.
The transaction includes a planned financing of $10 million to $15 million earmarked to fund development of Cortigent’s neurostimulation technology and product portfolio. This signals a pivot in ClearOne’s business focus toward medical technology.
ClearOne’s share price is US$6.48, with the stock up 101.2% over the past day. This highlights how sensitive the shares can be to major corporate announcements and proposed capital plans.
This merger points to a fundamental reshaping of what ClearOne will be going forward. Execution risk around integrating a medical device business and deploying new funding is likely to be central to how the market values the combined company. Announcement • Jul 02
Cortigent, Inc. entered into a definitive agreement and plan of merger to acquire ClearOne, Inc. (NasdaqCM:CLRO) in a reverse merger transaction for $40.3 million. Cortigent, Inc. entered into a definitive agreement and plan of merger to acquire ClearOne, Inc. (NasdaqCM:CLRO) in a reverse merger transaction for $40.3 million on July 2, 2026. Under the terms of the acquisition, Vivani Medical, Inc. will receive 12,500,000 shares of common stock in the capital of ClearOne, Inc. It is anticipated that Vivani Medical, Inc. will own 59.4% to 67.5% of the outstanding equity in the combined company and the former shareholders of ClearOne, Inc. will own 12.7% to 14.4% of the outstanding equity in the Combined Company. ClearOne, Inc. will be renamed “Cortigent Holdings, Inc” (d/b/a Cortigent) and is expected to trade under Nasdaq ticker symbol “CRGT.” Upon Closing, the Combined Company will be majority-owned by Vivani and will operate independently under the oversight of the reconstituted board of directors.
The transaction is subject to customary closing conditions, including receipt of the required stockholder approvals, closing of the Financing, meeting the minimum net cash requirements set forth in the Agreement, and the continued listing of the Combined Company’s common stock on Nasdaq. The deal has been unanimously approved by the board of directors of ClearOne, Inc. and Vivani Medical, Inc. The transaction is expected to close in the third quarter of 2026.
ThinkEquity LLC acted as sole financial advisor to Vivani Medical, Inc. 
